泰恩康上半年营收、净利双降

Core Insights - The company, 泰恩康, reported a decline in revenue and net profit for the first half of 2025, with revenue at 347 million yuan, down 12.23% year-on-year, and net profit at 37.08 million yuan, down 56.75% [1] Revenue Breakdown - The core segment of gastrointestinal medications saw a revenue increase of 103.39 million yuan, reflecting a year-on-year growth of 11.04% [1] - Revenue from ophthalmic medications was 79.38 million yuan, showing a decrease of 9.02% year-on-year [1] - The revenue from sexual health medications dropped significantly to 66.74 million yuan, a decline of 48.75% year-on-year, attributed to increased competition and a rise in the number of competing products [1]